Apogee Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Fairmount Funds Management and related entities updated their beneficial ownership in Apogee Therapeutics, Inc. to 9.99% following a recent public offering.
NASDAQ
Fairmount Healthcare Fund II L.P. sold 1.75 million shares of Apogee Therapeutics common stock for $76.30 per share, reducing its beneficial ownership.
NASDAQ
Fairmount Healthcare Fund II L.P. entered into a 60-day lock-up agreement for its Apogee Therapeutics shares following a public offering.